Prevalence Of People With Diabetes Who Meet Therapeutic Targets In Different Risk Factors - The Reality Of A List
DOI:
https://doi.org/10.58043/rphrc.73Keywords:
Risco cardiovascular, Diabetes MellitusAbstract
Introduction: The key role that HbA1c and blood pressure control plays in reducing microvascular complications in Diabetes Mellitus (DM) is currently known. The optimization of the blood pressure (BP) profile and dyslipidemia reduces the appearance of cardiovascular disease (CVD), one of the main causes of death in people with diabetes.
Type of study: Analytical retrospective observational study.
Methodology: Inclusion of patients with DM aged %E2%89%A520 years enrolled and attending a list, between January and October 2021. The BP values used resulted from the average of the last 2 records in SClinico%C2%AE, measured in consultation, with a calibrated and validated automatic sphygmomanometer. Clinical records: lipid profile, HbA1c and cardiovascular risk (CVR) calculated at the last visit.
Results: Inclusion of 92 patients, 52.2% women and 47.8% men. Ages ranged between 53 and 94 years, with a mean age of 72 years. Only 57.6% had good glycemic control (A) and of the BP values (B), only 55.8% of individuals with high CVR and 44.9% of those with very high CVR had values within the target. There were greater control of CT (C) (90.7%), LDL (46.5%) and TRG (74.4%) in diabetics with high CVR, compared to individuals with very high CVR (75.5% ; 22.4% and 57.1% respectively). We found a higher prevalence of individuals meeting the ABC criteria, 25.0% (n=23), compared to the STARK study (2010), in which 18.8% met targets according to the American Diabetes Association (ADA). Defining current target values, ESC 2021 recommendations, only 16.3% (n=15) met the ABC criteria.
Conclusion: Diabetic control rates are still below expectations, despite progress in the surveillance and control of these users in recent decades. There is still a need for greater investment in prevention strategies, control of CVR factors and earlier and more intensive pharmacological intervention to prevent and/or delay the complications of DM.
Downloads
References
Visseren FLJ, MacH F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.
Cardiovascular ESC. SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54.
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
Cardiovascular R. Avaliação do Risco Cardiovascular SCORE ( Systematic Coronary Risk Evaluation ) Risco Cardiovascular Médicos e Enfermeiros do Sistema Nacional de Saúde Departamento da Qualidade na Saúde ( dqs@dgs.pt ). 2013;1–13.
Casagrande SS, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013;36(8):2271–9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Cristina Pais, Rosa de Pinho
This work is licensed under a Creative Commons Attribution 4.0 International License.
